Curative cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis and synchronous resectable liver metastases arising from colorectal cancer

Lorimier, G.; Linot, Benjamin; Paillocher, N.; Dupoiron, Denis; Verriele, Véronique; Wernert, Romuald; Hamy, A.; Capitain, Olivier

doi:10.1016/j.ejso.2016.09.010

Cited by 36 publications

(45 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…1). Of the 24 cohort studies, six 18,34,37,40,44,47 were prospective and the remaining 18 11,20,[31][32][33]35,36,38,39,[41][42][43]45,46,[48][49][50][51] were retrospective (Table S1, supporting information).…”

Section: Resultsmentioning

confidence: 99%

“…Five studies 18,31,43,52,53 reported on the influence of Eastern Cooperative Oncology Group (ECOG) status on OS, and three presented adequate data to be included in the meta-analysis. The pooled unadjusted HR for an ECOG score of at least 2 was 1⋅77 (95 per cent c.i.…”

Section: Eastern Cooperative Oncology Group Performance Statusmentioning

confidence: 99%

“…Eight studies 20,34,36,40,43,47,53,54 reported on the influence of a rectal or colonic primary on OS and six presented adequate data to be included in the meta-analysis. The pooled unadjusted HR for rectal primary (compared with colonic primary) was 1⋅48 (95 per cent c.i.…”

Section: Rectal or Colonic Primarymentioning

confidence: 99%

“…Four studies 11,43,46,49 reported on the influence of mucinous histology on OS. Three studies presented adequate data to be included in the meta-analysis.…”

Section: Mucinous Histologymentioning

confidence: 99%

See 3 more Smart Citations

Meta‐analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy

et al. 2019

View full text Add to dashboard Cite

Background: Up to 15 per cent of colorectal cancers present with peritoneal metastases (CPM). Cytoreductive surgery and heated intraperitoneal chemotherapy (CRS + HIPEC) aims to achieve macroscopic tumour resection combined with HIPEC to destroy microscopic disease. CRS + HIPEC is a major operation with significant morbidity and effects on quality of life (QoL). Improving patient selection is crucial to maximize patient outcomes while minimizing morbidity and mortality. The aim of this study was to identify prognostic factors for patients with CPM undergoing CRS + HIPEC. Methods: A systematic search of MEDLINE, Embase and Cochrane Library electronic databases was performed using terms for colorectal cancer, peritoneal metastasis and CRS + HIPEC. Included studies focused on the impact of prognostic factors on overall survival following CRS + HIPEC in patients with CPM. Results: Twenty-four studies described 3128 patients. Obstruction or perforation of the primary tumour (hazard ratio (HR) 2⋅91, 95 per cent c.i. 1⋅5 to 5⋅65), extent of peritoneal metastasis as described by the Peritoneal Carcinomatosis Index (PCI) (per increase of 1 PCI point: HR 1⋅07, 1⋅02 to 1⋅12) and the completeness of cytoreduction (CC score above zero: HR 1⋅75, 1⋅18 to 2⋅59) were associated with reduced overall survival after CRS + HIPEC. Conclusion: Primary tumour obstruction or perforation, PCI score and CC score are valuable prognostic factors in the selection of patients with CPM for CRS + HIPEC.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Eastern Cooperative Oncology Group Performance Statusmentioning

confidence: 99%

Section: Rectal or Colonic Primarymentioning

confidence: 99%

“…Four studies 11,43,46,49 reported on the influence of mucinous histology on OS. Three studies presented adequate data to be included in the meta-analysis.…”

Section: Mucinous Histologymentioning

confidence: 99%

See 2 more Smart Citations

Meta‐analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Additionally, a recent meta-analysis reported a significantly higher risk of death (hazard ratio 1.30) for patients with both liver metastases and PM treated with curative intent compared to patients with isolated PM 56. In addition, several retrospective cohort studies reported similar or slightly impaired survival outcomes in patients with CRS and HIPEC for PM combined with liver surgery for hepatic metastases, along with similar treatment-related morbidity 57–59…”

Section: Liver Metastasesmentioning

confidence: 99%

Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer

Simkens

Rovers

Nienhuijs

et al. 2017

CMAR

View full text Add to dashboard Cite

Cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) is a viable option for selected patients with peritoneal metastases (PM) from colorectal origin, resulting in long-term survival and even cure in some cases. However, adequate patient selection for this treatment is currently one of the major challenges. The aim of this review is to provide a comprehensive overview of clinically relevant factors associated with overall survival. This may help to guide clinicians through the complex interplay of patient, tumor, and treatment characteristics to adequately select patients who benefit the most from this extensive surgical treatment. First, basic principles of colorectal PM and the CRS and HIPEC treatment will be discussed. According to available literature, especially extent of peritoneal disease, completeness of cytoreduction, and signet ring cell histology have great influence on the outcome after CRS and HIPEC. Other factors that seem to have a negative prognostic value are the presence of liver metastases and the absence of treatment with neo-adjuvant systemic therapy. Prognostic models combining the above-mentioned factors, such as the Colorectal Peritoneal Metastases Prognostic Surgical Score nomogram, may provide clinically relevant tools to use in everyday practice.

show abstract

Liver Resection and HIPEC

Enomoto

Levine

Shen

et al. 2019

Cancer Regional Therapy

View full text Add to dashboard Cite

Curative cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis and synchronous resectable liver metastases arising from colorectal cancer

Cited by 36 publications

References 39 publications

Meta‐analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy

Meta‐analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy

Patient selection for cytoreductive surgery and HIPEC for the treatment of peritoneal metastases from colorectal cancer

Liver Resection and HIPEC

Contact Info

Product

Resources

About